PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.

Abstract What's known on the subject? and What does the study add? Steroid hormone receptor signals have been implicated in bladder tumourigenesis and tumour progression. The expression of androgen and/or oestrogen receptors has been assessed in bladder cancer, leading to conflicting data of expression levels and their relationship to histopathological characteristics of the tumours. We simultaneously analyze three receptors in non-neoplastic bladder tissues as well as in primary and metastatic bladder tumour specimens. Our data demonstrate that the expression status correlates with tumour grades/stages and patients' outcomes.
PMID
Related Publications

Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.

Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence.

Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.

Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies.

Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.

Authors

Mayor MeshTerms
Keywords
Journal Title bju international
Publication Year Start




PMID- 22221549
OWN - NLM
STAT- MEDLINE
DCOM- 20120806
LR  - 20120508
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 109
IP  - 11
DP  - 2012 Jun
TI  - Expression of androgen and oestrogen receptors and its prognostic significance in
      urothelial neoplasm of the urinary bladder.
PG  - 1716-26
LID - 10.1111/j.1464-410X.2011.10706.x [doi]
AB  - UNLABELLED: What's known on the subject? and What does the study add? Steroid
      hormone receptor signals have been implicated in bladder tumourigenesis and
      tumour progression. The expression of androgen and/or oestrogen receptors has
      been assessed in bladder cancer, leading to conflicting data of expression levels
      and their relationship to histopathological characteristics of the tumours. We
      simultaneously analyze three receptors in non-neoplastic bladder tissues as well 
      as in primary and metastatic bladder tumour specimens. Our data demonstrate that 
      the expression status correlates with tumour grades/stages and patients'
      outcomes. OBJECTIVE: To assess the expression of the androgen receptor (AR) and
      oestrogen receptors (ERs) in bladder tumours because recent studies have shown
      conflicting results and the prognostic significance of their expression remains
      unclear. PATIENTS AND METHODS: We investigated the expression of AR, ERalpha and 
      ERbeta in 188 bladder tumour specimens, as well as matched 141 non-neoplastic
      bladder and 14 lymph node metastasis tissues, by immunohistochemistry. We then
      evaluated the relationships between their expression and the clinicopathological 
      features available for the present patient cohort. RESULTS: AR/ERalpha/ERbeta was
      positive in 80%/50%/89% of benign urothelium, 50%/67%/41% of benign stroma,
      42%/27%/49% of primary tumours and 71%/64%/71% of metastatic tumours.
      Significantly lower expression of AR/ERalpha was found in high-grade tumours
      (36%/23%) and tumours invading muscularis propria (33%/19%) compared to low-grade
      tumours (55%; P= 0.0232/38%; P= 0.0483) and tumours not invading muscularis
      propria (51%; P= 0.0181/35%; P= 0.0139), respectively. Significantly higher
      expression of ERbeta was found in high-grade tumours (58%) and tumours invading
      muscularis propria (67%) compared to low-grade tumours (29%; P= 0.0002) and
      tumours not invading muscularis propria (34%; P < 0.0001), respectively.
      Kaplan-Meier and log-rank tests further showed that positivity of ERbeta (but not
      AR or ERalpha) was associated with the recurrence of low-grade tumours (P=
      0.0072); the progression of low-grade tumours (P= 0.0005), high-grade tumours not
      invading muscularis propria (P= 0.0020) and tumours invading muscularis propria
      (P= 0.0010); or disease-specific mortality in patients with tumours invading
      muscularis propria (P= 0.0073). CONCLUSIONS: Compared to benign bladders, a
      significant decrease in the expression of AR, ERalpha or ERbeta in bladder cancer
      was seen. Loss of AR or ERalpha was strongly associated with higher grade/more
      invasive tumours, whereas ERbeta expression was increased in high-grade/invasive 
      tumours and predicted a worse prognosis.
CI  - (c) 2012 THE AUTHORS. BJU INTERNATIONAL (c) 2012 BJU INTERNATIONAL.
FAU - Miyamoto, Hiroshi
AU  - Miyamoto H
AD  - Department of Pathology Urology, University of Rochester Medical Center,
      Rochester, NY, USA.
FAU - Yao, Jorge L
AU  - Yao JL
FAU - Chaux, Alcides
AU  - Chaux A
FAU - Zheng, Yichun
AU  - Zheng Y
FAU - Hsu, Iawen
AU  - Hsu I
FAU - Izumi, Koji
AU  - Izumi K
FAU - Chang, Chawnshang
AU  - Chang C
FAU - Messing, Edward M
AU  - Messing EM
FAU - Netto, George J
AU  - Netto GJ
FAU - Yeh, Shuyuan
AU  - Yeh S
LA  - eng
PT  - Journal Article
DEP - 20120105
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Receptors, Androgen)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma/*metabolism/pathology/surgery
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Receptors, Androgen/*metabolism
MH  - Receptors, Estrogen/*metabolism
MH  - Urinary Bladder Neoplasms/*metabolism/pathology/surgery
MH  - Urothelium/metabolism/*pathology
EDAT- 2012/01/10 06:00
MHDA- 2012/08/07 06:00
CRDT- 2012/01/07 06:00
PHST- 2012/01/07 06:00 [entrez]
PHST- 2012/01/10 06:00 [pubmed]
PHST- 2012/08/07 06:00 [medline]
AID - 10.1111/j.1464-410X.2011.10706.x [doi]
PST - ppublish
SO  - BJU Int. 2012 Jun;109(11):1716-26. doi: 10.1111/j.1464-410X.2011.10706.x. Epub
      2012 Jan 5.